JP6456958B2 - Ｈｃｖポリメラーゼ阻害剤 - Google Patents

Ｈｃｖポリメラーゼ阻害剤 Download PDF

Info

Publication number
JP6456958B2
JP6456958B2 JP2016540848A JP2016540848A JP6456958B2 JP 6456958 B2 JP6456958 B2 JP 6456958B2 JP 2016540848 A JP2016540848 A JP 2016540848A JP 2016540848 A JP2016540848 A JP 2016540848A JP 6456958 B2 JP6456958 B2 JP 6456958B2
Authority
JP
Japan
Prior art keywords
mmol
alkyl
compound
group
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016540848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529324A5 (enExample
JP2016529324A (ja
Inventor
カラヤノフ，ジェナディ
トルッセル，スタッファン
ヴェーリング，ホルスト
Original Assignee
メディヴィル・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6456958(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メディヴィル・アクチエボラーグ filed Critical メディヴィル・アクチエボラーグ
Publication of JP2016529324A publication Critical patent/JP2016529324A/ja
Publication of JP2016529324A5 publication Critical patent/JP2016529324A5/ja
Application granted granted Critical
Publication of JP6456958B2 publication Critical patent/JP6456958B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016540848A 2013-09-04 2014-09-02 Ｈｃｖポリメラーゼ阻害剤 Active JP6456958B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE1351026-8 2013-09-04
SE1351026 2013-09-04
SE1351169 2013-10-03
SE1351169-6 2013-10-03
SE1450152 2014-02-12
SE1450152-2 2014-02-12
PCT/SE2014/051005 WO2015034420A1 (en) 2013-09-04 2014-09-02 Hcv polymerase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018193251A Division JP2019065011A (ja) 2013-09-04 2018-10-12 Ｈｃｖポリメラーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2016529324A JP2016529324A (ja) 2016-09-23
JP2016529324A5 JP2016529324A5 (enExample) 2017-10-19
JP6456958B2 true JP6456958B2 (ja) 2019-01-23

Family

ID=52628746

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016540848A Active JP6456958B2 (ja) 2013-09-04 2014-09-02 Ｈｃｖポリメラーゼ阻害剤
JP2018193251A Ceased JP2019065011A (ja) 2013-09-04 2018-10-12 Ｈｃｖポリメラーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018193251A Ceased JP2019065011A (ja) 2013-09-04 2018-10-12 Ｈｃｖポリメラーゼ阻害剤

Country Status (28)

Country Link
US (5) US9481703B2 (enExample)
EP (2) EP3041855B1 (enExample)
JP (2) JP6456958B2 (enExample)
KR (1) KR20160078337A (enExample)
CN (3) CN108558973A (enExample)
AU (2) AU2014315715B2 (enExample)
BR (1) BR112016004919A2 (enExample)
CA (1) CA2921899A1 (enExample)
CL (2) CL2016000493A1 (enExample)
CR (1) CR20160123A (enExample)
CY (1) CY1119587T1 (enExample)
DK (1) DK3041855T3 (enExample)
EA (1) EA028974B1 (enExample)
HR (1) HRP20171435T1 (enExample)
HU (1) HUE036365T2 (enExample)
IL (2) IL244389B (enExample)
ME (1) ME02875B (enExample)
MX (1) MX2016002849A (enExample)
MY (1) MY177804A (enExample)
PH (2) PH12016500402B1 (enExample)
PL (1) PL3041855T3 (enExample)
PT (1) PT3041855T (enExample)
RS (1) RS56383B1 (enExample)
SA (1) SA516370684B1 (enExample)
SG (2) SG10201700647PA (enExample)
SI (1) SI3041855T1 (enExample)
UA (1) UA117375C2 (enExample)
WO (1) WO2015034420A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
CN104151360B (zh) * 2013-05-14 2019-02-22 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
KR20160099090A (ko) * 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
WO2015081297A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3134423A4 (en) * 2014-04-24 2017-11-29 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2016015638A1 (zh) * 2014-07-30 2016-02-04 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
US10173971B2 (en) 2014-12-30 2019-01-08 Dow Agrosciences Llc Picolinamides with fungicidal activity
CN107426999B (zh) * 2014-12-30 2023-01-20 美国陶氏益农公司 具有杀真菌活性的吡啶酰胺化合物
KR20170100549A (ko) 2014-12-30 2017-09-04 다우 아그로사이언시즈 엘엘씨 살진균 활성을 갖는 피콜린아미드 화합물
UA121561C2 (uk) 2014-12-30 2020-06-25 Дау Аґросаєнсиз Елелсі Застосування сполук аміду як фунгіцидів
WO2016134057A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016140616A1 (en) * 2015-03-02 2016-09-09 Medivir Ab Nucleotide phosphoramidate formulation
HK1243712A1 (zh) * 2015-03-02 2018-07-20 美迪维尔公司 作为用於治疗丙型肝炎的hcv抑制剂的核苷酸衍生物
WO2016160646A1 (en) * 2015-04-02 2016-10-06 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
CN107709344B (zh) * 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
WO2017040889A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
EP3344642A1 (en) * 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
WO2017040896A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040895A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040892A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040898A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
SG10202109869XA (en) 2015-09-16 2021-10-28 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
CN105367505A (zh) * 2015-12-01 2016-03-02 苏利制药科技江阴有限公司 一种新型合成3,6-二甲基-2,5-哌嗪二酮的方法
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
WO2018033593A1 (en) * 2016-08-19 2018-02-22 Sandoz Ag Sofosbuvir derivatives for the treatment of hepatitis c
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
EP3618626A4 (en) 2017-05-02 2020-12-02 Dow Agrosciences LLC USE OF ACYCLIC PICOLINAMIDE COMPOUND AS A FUNGICIDE FOR THE CONTROL OF FUNGAL DISEASES ON TURF
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
US12221459B2 (en) 2018-03-09 2025-02-11 Medivir Ab Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
WO2020081382A1 (en) 2018-10-15 2020-04-23 Dow Agrosciences Llc Methods for sythesis of oxypicolinamides
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
CN114554848A (zh) 2019-10-18 2022-05-27 科迪华农业科技有限责任公司 用于合成吡啶酰胺的方法
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111269263A (zh) * 2020-03-09 2020-06-12 上海龙翔生物医药开发有限公司 一种瑞德西韦侧链中间体及其制备方法
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN111848679A (zh) * 2020-04-17 2020-10-30 山东科巢生物制药有限公司 一种利用微通道反应技术合成瑞德西韦的方法
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
HUE067491T2 (hu) 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN116199679A (zh) * 2022-12-23 2023-06-02 吉斯凯(苏州)制药有限公司 一种拉米夫定的工业化制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
ATE491459T1 (de) * 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US20090298708A1 (en) * 2006-08-23 2009-12-03 Masad Damha J 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis
HRP20110193T1 (hr) * 2006-10-10 2011-05-31 Medivir Ab Inhibitor hcv nukleozida
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JP2011508740A (ja) 2007-12-27 2011-03-17 エピファニー バイオサイエンシズ， インク． 抗ウイルス化合物
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
MX2011009728A (es) * 2009-03-20 2011-10-14 Alios Biopharma Inc Analogos nucleotido y nucleosido sustituidos.
CN101591371B (zh) * 2009-06-30 2012-05-30 连云港金康医药科技有限公司 一种通过卤交换氟化制备吉西他滨或其类似物的方法
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
US8402690B2 (en) 2010-09-09 2013-03-26 Sterling International Inc. Bedbug trap
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EA025341B1 (ru) * 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
KR20160099090A (ko) * 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
WO2015081297A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3134423A4 (en) 2014-04-24 2017-11-29 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer

Also Published As

Publication number Publication date
UA117375C2 (uk) 2018-07-25
SA516370684B1 (ar) 2017-05-10
CN105705510B (zh) 2018-11-30
EP3252066A1 (en) 2017-12-06
US20170107244A1 (en) 2017-04-20
US9828408B2 (en) 2017-11-28
HRP20171435T1 (hr) 2017-11-03
PL3041855T3 (pl) 2018-03-30
IL261702B (en) 2019-05-30
CL2019000271A1 (es) 2019-06-07
US20150175648A1 (en) 2015-06-25
US10106571B2 (en) 2018-10-23
EP3041855B1 (en) 2017-07-26
HK1255872A1 (zh) 2019-08-30
IL244389A0 (en) 2016-04-21
RS56383B1 (sr) 2017-12-29
CN108558973A (zh) 2018-09-21
AU2017203954A1 (en) 2017-07-06
PH12018500931A1 (en) 2019-02-04
CL2016000493A1 (es) 2016-12-23
PH12016500402A1 (en) 2016-05-16
CN108676047A (zh) 2018-10-19
PT3041855T (pt) 2017-11-08
SG10201700647PA (en) 2017-02-27
CA2921899A1 (en) 2015-03-12
US9540411B2 (en) 2017-01-10
BR112016004919A2 (pt) 2017-09-05
SI3041855T1 (sl) 2017-11-30
ME02875B (me) 2018-04-20
CN105705510A (zh) 2016-06-22
MY177804A (en) 2020-09-23
CR20160123A (es) 2016-07-20
IL244389B (en) 2018-10-31
US20160340380A1 (en) 2016-11-24
PH12016500402B1 (en) 2016-05-16
EP3252066B1 (en) 2019-05-22
DK3041855T3 (en) 2017-10-23
KR20160078337A (ko) 2016-07-04
MX2016002849A (es) 2016-10-26
US9481703B2 (en) 2016-11-01
US20180105549A1 (en) 2018-04-19
AU2014315715B2 (en) 2017-04-06
EP3041855A1 (en) 2016-07-13
AU2014315715A1 (en) 2016-03-10
JP2019065011A (ja) 2019-04-25
IL261702A (en) 2018-10-31
EA028974B1 (ru) 2018-01-31
JP2016529324A (ja) 2016-09-23
HK1221228A1 (zh) 2017-05-26
EA201690452A1 (ru) 2016-08-31
US20190085010A1 (en) 2019-03-21
HUE036365T2 (hu) 2018-07-30
CY1119587T1 (el) 2018-03-07
CN108676047B (zh) 2021-04-02
WO2015034420A1 (en) 2015-03-12
SG11201601474UA (en) 2016-03-30
AU2017203954B2 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
JP6456958B2 (ja) Ｈｃｖポリメラーゼ阻害剤
JP5624029B2 (ja) シクロプロピルポリメラーゼ阻害剤
US20130143835A1 (en) HCV Polymerase Inhibitors
WO2013084165A1 (en) Hcv polymerase inhibitors
JP2012510980A (ja) ウラシルシクロプロピルヌクレオチド
US20160271160A1 (en) Hcv polymerase inhibitors
TWI639613B (zh) Ｈｃｖ聚合酶抑制劑
TWI675664B (zh) Hcv聚合酶抑制劑
HK1247206A1 (en) Hcv polymerase inhibitors
HK1247206B (en) Hcv polymerase inhibitors
HK1255872B (en) Hcv polymerase inhibitors
HK1226412B (en) Hcv polymerase inhibitors
HK1226412A1 (en) Hcv polymerase inhibitors
HK1221228B (zh) Hcv聚合酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181219

R150 Certificate of patent or registration of utility model

Ref document number: 6456958

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250